Under these guidelines, full BRCA1/2 mutation screening is usually restricted to individuals affected by breast or epithelial ovarian cancer, and whose family history as a whole satisfies a ‘potentially high-risk category’ (NBCC Genetics Working Group, 2000; Nelson et al, 2005). Here, BRCA1 is linked to ovarian carcinoma.